Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16202
Title: L-Tyrosine confers residualizing properties to a d-Amino acid-rich residualizing peptide for radioiodination of internalizing antibodies
Austin Authors: Lee, Fook T;Burvenich, Ingrid JG;Guo, Nancy;Kocovski, Pece;Tochon-Danguy, Henri;Ackermann, Uwe ;O’Keefe, Graeme J;Gong, Sylvia;Rigopoulos, Angela;Liu, Zhanqi;Gan, Hui K ;Scott, Andrew M 
Affiliation: Austin Health, Heidelberg, Victoria, Australia
Tumour Targeting Program, Ludwig Institute For Cancer Research and Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 2016
Date: 2016-07-25
Publication information: Molecular Imaging 2016; online first: 25 July
Abstract: PURPOSE: The aims of the study were to develop and evaluate a novel residualizing peptide for labeling internalizing antibodies with (124)I to support clinical development using immuno-positron emission tomography (PET). METHODS: The anti-epidermal growth factor receptor antibody ch806 was radiolabeled directly or indirectly with isotopes and various residualizing peptides. Azido-derivatized radiolabeled peptides were conjugated to dibenzylcyclooctyne-derivatized ch806 antibody via click chemistry. The radiochemical purities, antigen-expressing U87MG.de2-7 human glioblastoma cell-binding properties, and targeting of xenografts at 72 hours post injection of all radioconjugates were compared. Biodistribution of (124)I-PEG4-tptddYddtpt-ch806 and immuno-PET imaging were evaluated in tumor-bearing mice. RESULTS: Biodistribution studies using xenografts at 72 hours post injection showed that (131)I-PEG4-tptddYddtpt-ch806 tumor uptake was similar to (111)In-CHX-A″-DTPA-ch806. (125)I-PEG4-tptddyddtpt-ch806 showed a lower tumor uptake value but higher than directly labeled (125)I-ch806. (124)I-PEG4-tptddYddtpt-ch806 was produced at 23% labeling efficiency, 98% radiochemical purity, 25.9 MBq/mg specific activity, and 64% cell binding in the presence of antigen excess. Tumor uptake for (124)I-PEG4-tptddYddtpt-ch806 was similar to (111)In-CHX-A″-DTPA-ch806. High-resolution immuno-PET/magnetic resonance imaging of tumors showed good correlation with biodistribution data. CONCLUSIONS: The mixed d/l-enantiomeric peptide, dThr-dPro-dThr-dAsp-dAsp-Tyr-dAsp-dAsp-dThr-dPro-dThr, is suitable for radiolabeling antibodies with radiohalogens such as (124)I for high-resolution immuno-PET imaging of tumors and for evaluation in early-phase clinical trials.
URI: https://ahro.austin.org.au/austinjspui/handle/1/16202
DOI: 10.1177/1536012116647535
Journal: Molecular Imaging
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/27457521
Type: Journal Article
Subjects: Residualizing peptide
Iodine-124
Antibodies
Internalization
Immuno-PET
Appears in Collections:Journal articles

Show full item record

Page view(s)

34
checked on Apr 19, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.